2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Elastase
  5. Elastase Inhibitor

Elastase Inhibitor

Elastase Inhibitors (47):

Cat. No. Product Name Effect Purity
  • HY-17443
    Sivelestat
    		Inhibitor 98.61%
    Sivelestat (EI546) is a competitive inhibitor of human neutrophil elastase, with an IC50 of 44 nM and a Ki of 200 nM. Sivelestat (EI546) has the potential for the study of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19.
  • HY-15651
    Alvelestat
    		Inhibitor 99.41%
    Alvelestat (AZD9668) is an orally bioavailable, affinity and selective inhibitor of neutrophil elastase (NE) with a pIC50 value of 7.9 nM, a Ki value of 9.4 nM and a Kd value of 9.5 nM.
  • HY-75957
    DMP 777
    		Inhibitor 99.75%
    DMP 777 is a potent, selective, and orally active human leukocyte elastase (HLE) inhibitor.
  • HY-17443B
    Sivelestat sodium tetrahydrate
    		Inhibitor 99.90%
    Sivelestat (EI546) sodium tetrahydrate is a competitive inhibitor of human neutrophil elastase, with an IC50 of 44 nM and a Ki of 200 nM. Sivelestat (EI546) sodium tetrahydrate has the potential for the study of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19.
  • HY-163411
    Neutrophil elastase inhibitor 6
    		Inhibitor
    Neutrophil elastase inhibitor 6 (compound 113) is an irreversible phosphonic-type inhibitor of human neutrophil elastase.
  • HY-17443BR
    Sivelestat sodium tetrahydrate (Standard)
    		Inhibitor
    Sivelestat (sodium tetrahydrate) (Standard) is the analytical standard of Sivelestat (sodium tetrahydrate). This product is intended for research and analytical applications. Sivelestat (EI546) sodium tetrahydrate is a competitive inhibitor of human neutrophil elastase, with an IC50 of 44 nM and a Ki of 200 nM. Sivelestat (EI546) sodium tetrahydrate has the potential for the study of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19.
  • HY-132132
    Neutrophil elastase inhibitor 3
    		Inhibitor
    Neutrophil elastase inhibitor 3 (compound 13), a benzoxazinone analog, shows effects on superoxide anion generation and exhibits as a neutrophil elastase (NE) inhibitor, with an IC50 of 80.8 nM for NE release.
  • HY-15891A
    GW311616 hydrochloride
    		Inhibitor 98.84%
    GW-311616 is a potent, orally bioavailable, long duration and selective human neutrophil elastase (HNE) inhibitor with IC50 value of 22 nM and Ki value of 0.31 nM.
  • HY-15891
    GW311616
    		Inhibitor 99.30%
    GW-311616 is a potent, orally bioavailable, long duration and selective human neutrophil elastase (HNE) inhibitor with IC50 value of 22 nM and Ki value of 0.31 nM.
  • HY-19908
    BAY-85-8501
    		Inhibitor 99.24%
    BAY-85-8501 is a selective, reversible and potent inhibitor of Human Neutrophil Elastase (HNE), with an IC50 of 65 pM.
  • HY-111457A
    BAY-678
    		Inhibitor 99.59%
    BAY-678 is an orally bioavailable, highly potent, selective and cell-permeable inhibitor of human neutrophil elastase (HNE), with an IC50 of 20 nM. BAY-678 is also nominated as a chemical probe to the public via the Structural Genomics Consortium (SGC).
  • HY-17443A
    Sivelestat sodium
    		Inhibitor 99.13%
    Sivelestat (EI546) sodium is a competitive inhibitor of human neutrophil elastase, with an IC50 of 44 nM and a Ki of 200 nM. Sivelestat (EI546) sodium has the potential for the study of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19.
  • HY-N6876
    Secologanoside
    		Inhibitor ≥99.0%
    Secologanoside is a triterpenoid isolated from Poraqueiba sericea, weakly inhibits elastase with an IC50 of 164 μg/mL. Secologanoside is moderate cytotoxic to fibroblasts.
  • HY-P3293A
    Lonodelestat TFA
    		Inhibitor 99.86%
    Lonodelestat TFA (POL6014 TFA) is a potent, orally active and selective peptide inhibitor of human neutrophil elastase (hNE). Lonodelestat TFA has the potential for the research of cystic fibrosis (CF).
  • HY-19254
    ZD-0892
    		Inhibitor
    ZD-0892 is a selective and potent inhibitor of a neutrophil elastase with Kis of 6.7 and 200 nM for human neutrophil elastase and porcine pancreatic elastase, respectively.
  • HY-19269
    FK706
    		Inhibitor 99.12%
    FK706 is a potent, slow-binding and competitive inhibitor of human neutrophil elastase with an IC50 of 83 nM and a Ki of 4.2 nM. FK706 also inhibits mouse neutrophil elastase and porcine pancreatic elastase with IC50s of 22 nM and 100 nM, respectively, and has no inhibitory activity against other serine proteinases such as human pancreatic trypsin, human pancreatic α-chymotrypsin and human leukocyte cathepsin G. FK706 has anti-inflammatory effect.
  • HY-P3293
    Lonodelestat
    		Inhibitor
    Lonodelestat (POL6014) is a potent, orally active and selective peptide inhibitor of human neutrophil elastase (hNE). Lonodelestat (POL6014) has the potential for the research of cystic fibrosis (CF).
  • HY-19406
    AE-3763
    		Inhibitor ≥98.0%
    AE-3763 is a peptide-based human neutrophil elastase inhibitor with an IC50 of 29 nM.
  • HY-N2395
    Chrysophanol 8-O-glucoside
    		Inhibitor 99.26%
    Chrysophanol 8-O-glucoside, from the roots of Rumex acetosa, shows moderate elastase inhibition activity.
  • HY-103445
    SSR69071
    		Inhibitor ≥98.0%
    SSR69071 is a potent, orally active and selective inhibitor of neutrophil elastase. SSR69071 reduces myocardial infarct size following ischemia-reperfusion injury. SSR69071 displays a higher affinity for human elastase (Ki=0.0168 nM) than for rat (Ki=3 nM), mouse (Ki=1.8 nM), and rabbit (Ki= 58 nM) elastases.